17 citations
,
February 2019 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” AKR1D1 controls glucocorticoid levels and receptor activity in liver cells.
16 citations
,
December 2001 in “The Journal of Dermatology” A woman recovered from hair loss and skin eruptions after stopping a tuberculosis drug and using steroids.
20 citations
,
October 2017 in “Stem Cell Reports” Alkaline Ceramidase 1 prevents early hair loss in mice by keeping hair follicle stem cells balanced.
1 citations
,
December 1970 in “European journal of endocrinology” Reversed sequential therapy with cyproterone acetate was effective for treating women with hirsutism and related conditions.
6 citations
,
February 2023 in “Journal of nanobiotechnology” The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
August 2024 in “Biomolecules & Therapeutics” A new compound, HTPI, promotes hair growth by protecting cells from damage and regulating energy use.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
42 citations
,
December 1976 in “PubMed” Cyproterone acetate and ethinylestradiol effectively reduce hirsutism and acne in women.
25 citations
,
October 2010 in “Journal of Hepatology” Budesonide alone is less effective than standard treatment for autoimmune hepatitis.
127 citations
,
August 2016 in “The oncologist” Understanding and managing side effects of hedgehog pathway inhibitors can improve treatment for advanced basal cell carcinoma.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
February 2023 in “Archives of Dermatological Research” A multi-tiered treatment approach is crucial for managing hidradenitis suppurativa in patients with intellectual and developmental disabilities.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
6 citations
,
November 2020 in “JAAD Case Reports” Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
22 citations
,
April 2010 in “Journal of Cellular Biochemistry” Certain mutations in the hairless protein disrupt its ability to regulate the hair cycle.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
37 citations
,
August 2011 in “Journal of Bone and Mineral Research” A girl had rickets due to a gene mutation affecting vitamin D response.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
October 2018 in “The American journal of gastroenterology” Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.